You are here

Article Text

Article menu

Download PDFPDF

Scientific Abstracts
Oral Presentations
Psoriatic arthritis - treatment
OP0229 THE GROUP FOR RESEARCH AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS (GRAPPA) TREATMENT RECOMMENDATIONS 2021
Free
  1. L. C. Coates1,
  2. E. Soriano2,
  3. N. Corp3,
  4. H. Bertheussen4,
  5. K. Callis-Duffin5,
  6. C. Barbosa Campanholo6,
  7. J. Chau7,
  8. L. Eder8,
  9. D. Fernandez9,
  10. O. Fitzgerald10,
  11. A. Garg11,
  12. D. D. Gladman12,
  13. N. Goel13,14,
  14. S. Grieb15,
  15. P. Helliwell16,
  16. M. E. Husni17,
  17. D. Jadon18,
  18. A. Katz19,
  19. D. Laheru20,
  20. J. Latella21,
  21. Y. Y. Leung22,
  22. C. Lindsay23,
  23. E. Lubrano24,
  24. L. Mazzuoccolo25,
  25. R. Mcdonald26,
  26. P. J. Mease27,28,
  27. D. O’sullivan29,
  28. A. Ogdie30,
  29. W. Olsder31,
  30. L. Schick15,
  31. I. Steinkoenig32,
  32. M. De Wit33,
  33. D. Van der Windt34,
  34. A. Kavanaugh35
  1. 1University of Oxford, NDORMS, Oxford, United Kingdom
  2. 2Hospital Italiano de Buenos Aires, Rheumatology, Buenos Aires, Argentina
  3. 3Keele University, School of Primary, Community and Social Care, Keele, United Kingdom
  4. 4GRAPPA, Patient Research Partner, Oslo, Norway
  5. 5University of Utah, Dermatology, Salt Lake City, United States of America
  6. 6Santa Casa de Sao Paulo, Rheumatology, Sao Paulo, Brazil
  7. 7GRAPPA, Patient Research Partner, Hong Kong, Hong Kong (SAR)
  8. 8University of Toronto, Rheumatology, Toronto, Canada
  9. 9Hospital Universitario San Ignacio, Rheumatology, Bogota, Colombia
  10. 10University College Dublin, Rheumatology, Dublin, Ireland
  11. 11Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Dermatology, Hempstead, United States of America
  12. 12Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, Canada
  13. 13GRAPPA, Patient Research Partner, Durham, United States of America
  14. 14Duke University, Rheumatology, Durham, United States of America
  15. 15GRAPPA, Patient Research Partner, Seattle, United States of America
  16. 16University of Leeds, Leeds Institute of Rheumatology and Musculoskeletal Medicine, Leeds, United Kingdom
  17. 17Cleveland Clinic Main Campus, Rheumatology, Cleveland, United States of America
  18. 18University of Cambridge, Rheumatology, Cambridge, United Kingdom
  19. 19GRAPPA, Patient Research Partner, Haifa, Israel
  20. 20Churchill Hospital, Dermatology, Oxford, United Kingdom
  21. 21GRAPPA, Patient Research Partner, Connecticut, United States of America
  22. 22Singapore General Hospital, Rheumatology, Singapore, Singapore
  23. 23GRAPPA, Patient Research Partner, Propser, United States of America
  24. 24University of Molise, Rheumatology, Campobasso, Italy
  25. 25Hospital Italiano de Buenos Aires, Dermatology, Buenos Aires, Argentina
  26. 26GRAPPA, Patient Research Partner, Toronto, Canada
  27. 27Swedish Medical Center, Rheumatology, Seattle, United States of America
  28. 28University of Washington, Rheumatology, Seattle, United States of America
  29. 29GRAPPA, Patient Research Partner, Dublin, Ireland
  30. 30University of Pennsylvania, Rheumatology, Philadelphia, United States of America
  31. 31GRAPPA, Patient Research Partner, Eindhoven, Netherlands
  32. 32GRAPPA, Patient Research Partner, Cleveland, United States of America
  33. 33GRAPPA, Patient Research Partner, Amsterdam, Netherlands
  34. 34Keele University, School of Primary Community and Social Care, Keele, United Kingdom
  35. 35University of California San Diego, Rheumatology, La Jolla, United States of America

Abstract

Background: Since the 2015 GRAPPA treatment recommendations were published, therapeutic options and management strategies for psoriatic arthritis (PsA) have advanced considerably.

Objectives: The goal of the GRAPPA recommendations update is to develop high quality, evidence-based recommendations for the treatment of PsA, including related conditions and comorbidities.

Methods: GRAPPA rheumatologists, dermatologists and patient research partners (PRPs) updated overarching principles for the management of adults with PsA by consensus. Principles considering use of biosimilars and tapering/discontinuing of therapy were added to this update. Systematic literature searches based on data publicly available from three databases (MEDLINE, EMBASE, and Cochrane CENTRAL) were conducted from the end of the previous recommendations’ searches through August 2020. Additional abstract searches were performed for conference presentations in 2017-2020. Searches covered PsA treatments (peripheral arthritis, axial arthritis, enthesitis, dactylitis, skin, and nail disease). Additional searches were performed for related conditions (uveitis and IBD) and comorbidities evaluating their impact on safety and treatment outcomes. Individual groups assessed the risk of bias and applied the GRADE system to generate strong or conditional recommendations for therapies within the domain groups and for the management of comorbidities and related conditions. These recommendations were then incorporated into an overall treatment schema.

Results: Updated, evidence-based treatment recommendations are shown (Table 1). Since 2015, many new medications have been incorporated. Additional results for older medications, such as methotrexate, have been published across PsA domains. Based on the evidence, the treatment recommendations developed by individual groups were incorporated into the overall schema including principles for management of arthritis, spondylitis, enthesitis, dactylitis, skin, and nail disease in PsA, and associated conditions (Figure 1). Choice of therapy for an individual should ideally address all of the domains that impact on that patient, supporting shared decision making with the patient involved. Additional consideration in the recommendations was given to key associated conditions and comorbidities as these often impact on therapy choice.

Conclusion: These GRAPPA treatment recommendations provide up to date, evidence-based guidance to providers who manage and treat adult patients with PsA. These recommendations are based on domain-based strategy for PsA and supplemented by overarching principles developed by consensus of GRAPPA members.

View this table:

Disclosure of Interests: Laura C Coates Speakers bureau: AbbVie, Amgen, Biogen, Celgene, Gilead, Eli Lilly, Janssen, Medac, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Amgen, Celgene, Eli Lilly, Pfizer, and Novartis, Enrique Soriano Speakers bureau: AbbVie, Amgen, Bristol-Myers Squibb,GSK, Genzyme, Janssen, Lilly, Novartis, Pfizer, Roche, Sandoz, Sanofi, UCB, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb,GSK, Genzyme, Janssen, Lilly, Novartis, Pfizer, Roche, Sandoz, Sanofi, UCB, Grant/research support from: AbbVie, Janssen, Novartis Pharma, Pfizer, Roche, and UCB, Nadia Corp: None declared, Heidi Bertheussen Consultant of: Pfizer, Kristina Callis-Duffin Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Lilly, Janssen, Novartis, Pfizer, Sienna Biopharmaceuticals, Stiefel Laboratories, UCB, Ortho Dermatologics, Inc, Regeneron Pharmaceuticals, Inc., Anaptys Bio, Boehringer Ingelheim., Cristiano Barbosa Campanholo Speakers bureau: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Jeffrey Chau: None declared, Lihi Eder Consultant of: Abbvie, UCB, Janssen, Eli Lily, Pfizer, Novartis, Grant/research support from: Abbvie, UCB, Janssen, Eli Lily, Pfizer, Novartis, Daniel Fernandez Consultant of: Abbvie, UCB, Roche, Janssen, Pfizer, Amgen and Brystol, Grant/research support from: Abbvie, UCB, Roche, Janssen, Pfizer, Amgen and Brystol, Oliver FitzGerald Speakers bureau: AbbVie, Janssen and Pfizer Inc, Consultant of: BMS, Celgene, Eli Lilly, Janssen and Pfizer Inc, Grant/research support from: AbbVie, BMS, Eli Lilly, Novartis and Pfizer Inc, Amit Garg Consultant of: Abbvie, Amgen, Asana Biosciences, Bristol Myers Squibb, Boehringer Ingelheim, Incyte, InflaRx, Janssen, Pfizer, UCB, Viela Biosciences, Grant/research support from: Abbvie, Dafna D Gladman Consultant of: Abbvie, Amgen, BMS, Eli Lilly, Galapagos, Gilead, Jansen, Novartis, Pfizer and UCB, Grant/research support from: Abbvie, Amgen, Eli Lilly, Jansen, Novartis, Pfizer and UCB, Niti Goel: None declared, Suzanne Grieb: None declared, Philip Helliwell Speakers bureau: Janssen, Novartis, Pfizer, Consultant of: Eli Lilly, M Elaine Husni Consultant of: Abbvie, Amgen, Janssen, Novartis, Lilly, UCB, Regeneron, and Pfizer, Deepak Jadon Speakers bureau: AbbVie, Amgen, Celgene, Eli Lilly, Gilead, Healthcare Celltrion, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, UCB, Consultant of: AbbVie, Amgen, Celgene, Eli Lilly, Gilead, Healthcare Celltrion, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, UCB, Grant/research support from: AbbVie, Amgen, Celgene, Eli Lilly, Gilead, Healthcare Celltrion, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, UCB, Arnon Katz: None declared, Dhruvkumar Laheru: None declared, John Latella: None declared, Ying Ying Leung Speakers bureau: Novartis, AbbVie, Eli Lilly, Janssen, Consultant of: Pfizer and Boehringer Ingelheim, Grant/research support from: Pfizer and conference support from AbbVie, Christine Lindsay Shareholder of: Amgen, Employee of: Aurinia pharmaceuticals, Ennio Lubrano Speakers bureau: Alfa-Sigma, Abbvie, Galapagos, Janssen Cilag, Lilly., Consultant of: Alfa-Sigma, Abbvie, Galapagos, Janssen Cilag, Lilly., Luis Mazzuoccolo Speakers bureau: Abbvie, Amgen, Novartis, Elli Lilly, Jansen, Consultant of: Abbvie, Amgen, Novartis, Elli Lilly, Jansen, Roland McDonald: None declared, Philip J Mease Speakers bureau: AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galapagos, Gilead Sciences, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN and UCB, Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead Sciences, Janssen, Novartis, Pfizer, SUN and UCB, Denis O’Sullivan: None declared, Alexis Ogdie Consultant of: AbbVie, Amgen, BMS, Celgene, Corrona, Gilead, Janssen, Lilly, Novartis, and Pfizer, Grant/research support from: Novartis and Pfizer and Amgen, Wendy Olsder: None declared, Lori Schick: None declared, Ingrid Steinkoenig: None declared, Maarten de Wit Consultant of: AbbVie, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, Roche, Danielle van der Windt: None declared, Arthur Kavanaugh Speakers bureau: AbbVie, Amgen, BMS, Eli Lilly, Gilead Janssen, Novartis, Pfizer, UCB, Consultant of: AbbVie, Amgen, BMS, Eli Lilly, Gilead Janssen, Novartis, Pfizer, UCB

Figure

https://doi.org/10.1136/annrheumdis-2021-eular.4091

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.